Australia markets close in 38 minutes

Icosavax, Inc. (ICVX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
28.08+1.35 (+5.05%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close26.73
Open26.67
Bid0.00 x 1000
Ask0.00 x 1200
Day's range26.67 - 28.75
52-week range21.70 - 49.99
Volume70,177
Avg. volume253,970
Market cap1.106B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-9.24
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est50.00
  • GlobeNewswire

    Icosavax Reports Second Quarter 2021 Financial Results and Provides Corporate Update

    - Initiated a Phase 1/2 clinical trial for IVX-411, a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain - - Initiated a Phase 1/1b clinical trial for IVX-121, a VLP displaying a Respiratory Syncytial Virus (RSV) stabilized pre-fusion F antigen - - Raised $209.3 million in gross proceeds from an upsized IPO, funding operations through at least 2024 - SEATTLE, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its inno

  • GlobeNewswire

    Icosavax Appoints Elizabeth Bekiroğlu to General Counsel

    SEATTLE, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the appointment of Elizabeth Bekiroğlu to General Counsel. “Elizabeth is an accomplished leader who has established an expertise in providing legal counsel to biotechnology and healthcare companies,” said Adam Simpson, Chief Executive Officer of Icosavax. “I a

  • GlobeNewswire

    Icosavax Initiates Phase 1/1b Trial of VLP Vaccine Candidate Against Respiratory Syncytial Virus

    - Phase 1/1b clinical trial will assess the safety and immunogenicity of IVX-121 in healthy adults, including older adults -SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the initiation of a Phase 1/1b clinical trial of IVX-121, a VLP displaying a Respiratory Syncytial Virus (RSV) stabilized pre-fusion F a